askIatroX now includes regulator-approved medicines data from emc

When you ask askIatroX a clinical question, the answer is grounded in established clinical guidelines and peer-reviewed literature. Through a strategic partnership with Datapharm — the company behind emc — it now also draws on the full Summary of Product Characteristics (SmPC) for every medicine listed on emc, the regulator-approved, manufacturer-maintained source most UK clinicians already use.

Guidelines tell you what to prescribe. The SmPC tells you the rest: dosing in renal impairment, interactions, contraindications in pregnancy, monitoring requirements that differ between brands. All now synthesised alongside guideline content in each query response.

What's changed in practice

Ask askIatroX about a drug and the response will integrate SmPC data where it's clinically relevant — dose adjustments, adverse effect profiles, special populations, storage, reconstitution. The SmPC content is continuously updated by manufacturers and delivered via emc, Datapharm's content distribution engine.

Nothing changes about how you use askIatroX. The source layer has expanded; the experience hasn't.

Why Datapharm

Datapharm publishes and maintains emc, the UK's most widely used medicines information resource. Every SmPC on the platform is the current, MHRA-approved version submitted by the marketing authorisation holder. It is a primary source for UK medicines data, and this strategic partnership allows iatroX to integrate it directly into a decision-support and clinical reference workflow.

What this means for iatroX

iatroX continues to expand the evidence base that powers askIatroX, with sources that meet the same standard — regulator-approved, continuously maintained, and already trusted by the clinicians who rely on them.